Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with…

By M. Fukuoka, Yi-long Wu, S. Thongprasert, P. Sunpaweravong, S. Leong, V. Sriuranpong, T. Chao, K. Nakagawa, D. Chu, N. Saijo and 8 more. Journal of Clinical Oncology, 2011

1,574 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/1ed424567d9371bd50f492109741990d6267b984

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. B. Chan
2. B. Hughes
3. Marc Ladanyi

Citations in the corpus

• Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. (2016, background): “33).(30) Similarly, another phase III study of gefitinib versus carboplatin plus paclitaxel in patients with EGFR-sensitizing mutations also found an improvement in PFS but not OS, again presumably secondarily to crossover to chemotherapy in the gefitinib arm.”
• Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. (2015, methodology): “IPASS met its primary endpoint with a 12-month progression-free survival (PFS) of 24.9% with gefitinib versus 6.7% with chemotherapy (39).”
• Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. (2013, neutral): “Upper respiratory infection† 44 (26) 0 22 (13) 1 (<1)”